Objectives: Sexually transmitted infections due to Chlamydia trachomatis (C. trachomatis) are a worldwide public health problem. The aim of this study was to investigate the drug susceptibilities of C. trachomatis strains isolated from the urethra and pharynx of Japanese males.
Introduction
The spread of sexually transmitted infections, particularly male urethritis and uterine cervicitis due to Chlamydia trachomatis (C. trachomatis), is a major worldwide health concern [1] [2] [3] . In Japanese guidelines published between 2014 and 2016, macrolides, tetracyclines and fluoroquinolones are the recommended treatment for genitourinary tract infections due to C. trachomatis [4, 5] . However, male urethritis and cervicitis are also transmitted from the pharynx during oral sex [6, 7] . Several studies have reported that pharyngeal chlamydial infection is refractory to some antimicrobial regimens [8] [9] [10] [11] . Since one of the reasons might be a low penetration rate of antimicrobial agents into the pharynx [11] , there is the possibility that the lower drug susceptibility of C. trachomatis cannot be overcome. However, while drug-resistant strains of C. trachomatis have been observed in other countries [12] [13] [14] [15] , there have also been reports of high drug susceptibilities in strains isolated from the urethras of Japanese males [16] . The aim of this study is to investigate the drug susceptibilities of C. trachomatis strains isolated from both the urethra and the pharynx of Japanese males.
The target drugs, levofloxacin and azithromycin, are recommended in the treatment 6 guidelines and are the most frequently administered antimicrobials by clinicians for C. trachomatis infection in Japan.
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Materials and Methods
Specimens were obtained from male patients diagnosed with urethritis or patients who wanted to check for the presence of urethritis at Okayama University Hospital, Araki Urology Clinic and Hirashima Clinic located in Okayama, Japan between 2013 and 2014.
Patient characteristics
Patient characteristics were ascertained from the medical records of patients for whom C. trachomatis was isolated from the urethra or pharynx. The following characteristics were noted: age, presence of symptoms caused by urethritis, and results of nucleic acid amplification testing of urine samples. Antimicrobial administration and treatment outcome were not included because the objective of this study was to survey for the presence of drug-resistant C. trachomatis strains.
Clinical specimens and chlamydial cultures for isolation of C. trachomatis
A cotton swab (Copan Diagnostics Inc., Italy) was inserted into throat and swab the pharynx. For urethra, a cotton swab was gently inserted about 3 cm into the urethra and gently rotated. Each swab was placed in a tube containing 0.5 mL of 10mM 8 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) • NaOH buffer containing sucrose (0.075g/ml) and L-glutamic acid (0.72mg/ml) buffer with micro beads followed by preservation at -70°C until cultured for Chlamydia spp.
We performed chlamydial culture of clinical swab specimens using a previously described method [17] . Frozen tubes containing swabs were quickly thawed in a water tank set at 37°C, after which the tubes were stirred using a vortex mixer to 60 min) using a Hitachi himac CR21E centrifuge (Hitachi Koki Co. Ltd., Tokyo, Japan)
to adhere chlamydial organisms to epithelial cells. One mL of Dulbecco's modified Eagle medium (DMEM; Nissui, Tokyo, Japan) including 1 g/ml of cycloheximide, 10 g/ml of kanamycin, 10 g/ml of vancomycin, 10 g/ml of amphotericin B and supplemented with 10% heat-inactivated fetal bovine serum (FBS; Gibco BRL, Life
Technologies Inc., Grand Island, NY, USA) was added to each well, and the inoculated cells were incubated at 37°C in 5% CO2. Cell conditions were monitored, at appropriate intervals using a phase-contrast microscope, for evidence of the cytopathic effect.
Immediately following observation of cell bursts, the cells were removed from the plates with sterile rubber fragments, suspended in 1 mL/well of sucrose-phosphate-glutamate (SPG) buffer and preserved at -70°C.
Fluorescent staining
Fluorescent staining to observe chlamydial inclusion was performed as previously described [17] . [18] .
Drug susceptibility testing
Drug susceptibility testing was performed according to the standard method of the Japanese Society of Chemotherapy [19] . Two antimicrobial agents, levofloxacin (LVFX; Daiichi Sankyo, Co., Ltd., Tokyo, Japan) and azithromycin (AZM; Pfizer Inc., New York, NY, USA), which are recommended in treatment guidelines [4, 5] were chosen for susceptibility testing. LVFX and AZM were obtained for a fee from Sigma-Aldrich Co. Ltd. and LKT Laboratories, Inc., respectively.
Preliminary experiments
Preliminary experiments using standard strains of C. trachomatis, including a reference strain, were performed to evaluate the quality of the HeLa229 cell line and the drug-susceptibility measuring system [19] . HeLa229 cells purchased from the National Institute of Infectious Diseases were cultured as described above in DMEM containing 10% heat-inactivated FBS. Cell conditions were monitored at appropriate intervals using a phase-contrast microscope. Chlamydial strains used in these preliminary experiments included serovar A, C, D/UW-3/Cx (reference strain), F, G and H. The
MICs of LVFX and AZM against these strains were measured before testing of the clinical isolates. 
Results
Patient characteristics
A total of 18 patients diagnosed as urethritis due to C. trachomatis were picked up from our database and enrolled in this study. The mean age of the 18 patients was 25.7±7.8
years. Symptoms included micturition pain in 8 patients, pus discharge in 4 patients, both in 4 patients and none in 1 patient. Pharyngitis symptomology was not observed.
All patients were diagnosed with chlamydial urethritis by polymerase chain reaction Table 1 ). The AZM MICs of serovar A, C, D/UW-3/Cx (reference strain), F, and G were all 0.25 μg/mL (Table 1) .
Neither the HeLa229 cell line nor the standard C. trachomatis strains, including the D/UW-3/Cx reference strain, exhibited unsuitability for use in the study.
In vitro drug susceptibility
During the 18 patients, C. trachomatis strains were isolated from only their urethra in 11 patients, and C. trachomatis strains were isolated from both their urethra and pharynx in 7 patients. Namely, 18 strains isolated from urethra and 7 strains isolated from pharynx were evaluated.
Drug susceptibilities of the clinical isolates are shown in Table 2 . The MICs of LVFX and AZM against urethral isolates ranged from 0.125 μg/mL to 0.5 μg/mL.
MIC50/MIC90 values of LVFX and AZM were 0.25/0.5 μg/mL and 0.25/0.25 μg/mL, respectively. In contrast, the LVFX and AZM MICs of chlamydial strains isolated from 14 the pharynx ranged from 0.125 μg/mL to 0.5 μg/mL and from 0.125 μg/mL to 0.25 μg/mL, respectively. MIC50/MIC90 values of LVFX and AZM were 0.5/0.5 μg/mL and 0.25/0.25 μg/mL, respectively. In patients from whom chlamydial strains were isolated from both the urethra and the pharynx, the MICs of LVFX and AZM between strains isolated from urethra and pharynx were identical in all six patients (1 pharyngeal strain could not be evaluated and was not harvestable due to bacterial contamination that prevented measurement of the AZM MIC).
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Discussion
In the present study, the MICs of LVFX and AZM of 18 chlamydial strains isolated from urethra and 7 strains isolated from pharynx were measured using the standard method published by the Japanese Society of Chemotherapy.
Reports on the drug susceptibilities of C. trachomatis are available for both Japan and other countries. According to reports from foreign countries such as the USA and Russia, drug resistance of C. trachomatis has been observed with isolates from treatment refractory STIs [12] [13] [14] [15] ; however, similar results have not been reported from Japan. Takahashi et al. did not isolate drug-resistant C. trachomatis from the urethras of Japanese males [16] . In contrast, studies of drug susceptibilities in C. trachomatis pharyngeal isolates have not been published from any part of the world. Despite the small number of isolates in the present study, our results support the report from Takahashi et al. No drug-resistant strains of C. trachomatis were isolated from the urethra and pharynx in Japanese patients.
In the present study, the MICs of LVFX and AZM in chlamydial strains isolated from the urethra were 0.125-0.5 μg/mL and 0.125-0.25 μg/mL, respectively. Pharyngeal infection of C. trachomatis is a relatively recent focus of investigation, and it has been reported that pharyngeal infection of C. trachomatis is refractory against some antimicrobials [8] [9] [10] [11] . Chlamydial culturing from a pharyngeal specimen is very difficult due to the lower number of chlamydial organisms in a mouth wash; the invasive procedure for obtaining pharyngeal swab specimens; and frequent contamination by other organisms. The present study is the first report of C.
trachomatis strains isolated from the pharynx. No drug-resistant strains were observed in pharyngeal C. trachomatis isolates. Our results might be significant for clinicians who must treat patients at the first visit. Based on current surveillance trends, Japanese clinicians should administer antimicrobials against chlamydial infections as recommended by the published guidelines. However, drug-resistant C. trachomatis strains or treatment refractory STIs might appear in Japan in the near future, as they have in other countries [12] [13] [14] [15] . If clinicians face treatment-refractory cases, they should consider the presence of a drug-resistant C. trachomatis strain, penetration of antimicrobials into the tissue and other factors. Thus, the surveillance of drug-resistant C. trachomatis is a significant tool, and MICs should be measured despite the complicated (multi-step, time-and labor-intensive) procedure that must be used.
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There are some limitations in this study; first, as mentioned above, the present study included a small number of strains collected from a limited recruitment area;
second, specimens were cultured before MIC measurement without cloning (e.g., plaque cloning [20] ); third, pairs of chlamydial strains, isolated from urethra and pharynx of the same patient, should be evaluated their identity by ompA sequencing or multilocus sequence typing [21, 22] . While the collection of swab specimens is an invasive procedure, and the cloning of chlamydial strains and procedures for MIC measurements can be quite troublesome, larger and long-term surveillance for drug-resistant C. trachomatis is necessary in any country.
In conclusion, our data suggest that both LVFX and AZM are effective antimicrobials for sexually transmitted infections due to C. trachomatis in Japan.
Further studies that include a larger number of isolates, not only from the urethra and uterine cervix but also from the pharynx, are necessary for the surveillance of drug-resistant C. trachomatis. Table 1 
